Form 4: Armata Pharmaceuticals Director Sarah J. Schlesinger Reports Stock Option Grants

Director Sarah J. Schlesinger reports the acquisition of stock options in Armata Pharmaceuticals, Inc.

Summary

• On March 14, 2024, Sarah J. Schlesinger, a director of Armata Pharmaceuticals, Inc., was granted stock options.
• She received options to purchase 39,666 shares that vest upon the company's 2024 annual shareholders meeting, contingent on her continuous service.
• Additionally, she received options for 54,343 shares, vesting 50% on March 14, 2025, and 50% on March 14, 2026, also subject to continuous service.
• The exercise price for all options is $3.38.
• Following these transactions, Schlesinger directly owns options for a total of 94,009 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative performance, but rather aligns director incentives with shareholder value.

Positives

• The grant of stock options to a director aligns her interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options suggests an expectation of continued service from the director.

Industry Context

Stock option grants are a common form of compensation for directors in publicly traded companies, aligning their interests with shareholders and incentivizing company growth.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the pharmaceutical industry depending on company size, stage of development, and performance.
• Comparing Armata's director compensation to companies like Spero Therapeutics or Atea Pharmaceuticals, which are also in the clinical-stage biotechnology sector, could provide a benchmark.
• However, without detailed information on the overall compensation structure, it's difficult to assess whether the option grants are above or below industry averages.

Stakeholder Impact

• The stock option grants could have a slightly positive impact on shareholders by aligning the director's interests with the company's long-term success.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates